Form 8-K - Current report:
SEC Accession No. 0001104659-24-125265
Filing Date
2024-12-04
Accepted
2024-12-04 06:00:38
Documents
13
Period of Report
2024-12-03
Items
Item 1.01: Entry into a Material Definitive Agreement

Document Format Files

Seq Description Document Type Size
1 FORM 8-K tm2430032d1_8k.htm   iXBRL 8-K 28294
  Complete submission text file 0001104659-24-125265.txt   200600

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA nvax-20241203.xsd EX-101.SCH 3012
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE nvax-20241203_lab.xml EX-101.LAB 34240
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE nvax-20241203_pre.xml EX-101.PRE 22357
15 EXTRACTED XBRL INSTANCE DOCUMENT tm2430032d1_8k_htm.xml XML 3558
Mailing Address 700 QUINCE ORCHARD ROAD GAITHERSBURG MD 20878
Business Address 700 QUINCE ORCHARD ROAD GAITHERSBURG MD 20878 240-268-2000
NOVAVAX INC (Filer) CIK: 0001000694 (see all company filings)

EIN.: 222816046 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 000-26770 | Film No.: 241524641
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)